Streetwise Reports' Article Archives — Current Month (6)
FDA OKs Trial of Cell Reservoir in Thyroid Disease (03/10/2025)
In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report.
With Competitor Out, New Drug Gains Edge in Chronic Cough (03/10/2025)
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report.
New Drug for Major Depressive Disorder Gets Good Surprise (03/10/2025)
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report.
Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ (03/06/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock.
Canadian Healthcare Co. Showcases Stable FQ424 (03/06/2025)
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.
Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data (03/05/2025)
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next.
More Archives
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
